Lifecore Biomedical Inc., a Chaska maker of sterile injectable pharmaceutical products, is exploring strategic alternatives after warning of "substantial doubt about the company's ability to continue as a going concern."
Options include the sale of the company and further debt or equity financing, the company said in a late Thursday announcement.
The company lost more than two-thirds of its market value on Friday. Its stock plummeted 67.3% for the day in response to the company's announcement.
The company faces declining revenue. In a statement, Lifecore CEO James Hall said Lifecore is saddled with "near-term challenges ... with its current capital structure."
Five months ago, its California-based owner Landec Corp. renamed itself and relocated to Minnesota, where the company has a long history.
Lifecore said that it would start the strategic review process after trying to obtain forbearance agreements — temporary postponement of loan payments — from its lenders.
The company on Thursday also reported second quarter fiscal 2023 results, which showed a net loss of $12.4 million on revenue of $38.8 million. In the same period of fiscal 2022, the company made $4.2 million on revenue of $43.5 million.
Those overall results include sales from Landec's Curation Foods business, which Lifecore is in the process of divesting. The core Lifecore operations saw a second quarter revenue drop of 13%.